Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Dwyer

Showing results (201-210 of 260) with videos related to

Pageof 26
Sort By:
Bioorganic & Medicinal Chemistry Letters|November 25, 2010
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2Marc Labroli, Kamil Paruch, Michael P Dwyer, et al.
Bioorganic & Medicinal Chemistry Letters|May 16, 2006
Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonistsJ Robert Merritt, Laura L Rokosz, Kingsley H Nelson, et al.
Bioorganic & Medicinal Chemistry Letters|November 25, 2010
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1Michael P Dwyer, Kamil Paruch, Marc Labroli, et al.
Diabetes Care|August 9, 2023
Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 DiabetesFilipe A Moura, David D Berg, Andrea Bellavia, et al.
Bioorganic & Medicinal Chemistry Letters|May 15, 2021
Discovery of novel N-1 substituted pyrazolopyrimidinones as potent, selective PDE2 inhibitorsGregori J Morriello, Michael P Dwyer, Yili Chen, et al.
Molecular Cancer Therapeutics|February 16, 2011
Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screeningTimothy J Guzi, Kamil Paruch, Michael P Dwyer, et al.
Cell|June 2, 2026
Plant cell wall-plasma membrane attachments mediate stress resilience through cellulose synthase complexes and remorinsYue Rui, Magda Zaoralová, William P Dwyer, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitorsMichael P Dwyer, Kamil Paruch, Carmen Alvarez, et al.
Lancet (London, England)|March 7, 2026
Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trialMichel Azizi, Jenifer M Brown, Jamie P Dwyer, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|August 24, 2025
Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24John M Flack, Michel Azizi, Jenifer M Brown, et al.
Pageof 26

Showing results (201-210 of 260) with videos related to

Sort By:
Pageof 26
Bioorganic & Medicinal Chemistry Letters|November 25, 2010
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2Marc Labroli, Kamil Paruch, Michael P Dwyer, et al.
Bioorganic & Medicinal Chemistry Letters|May 16, 2006
Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonistsJ Robert Merritt, Laura L Rokosz, Kingsley H Nelson, et al.
Bioorganic & Medicinal Chemistry Letters|November 25, 2010
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1Michael P Dwyer, Kamil Paruch, Marc Labroli, et al.
Diabetes Care|August 9, 2023
Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 DiabetesFilipe A Moura, David D Berg, Andrea Bellavia, et al.
Bioorganic & Medicinal Chemistry Letters|May 15, 2021
Discovery of novel N-1 substituted pyrazolopyrimidinones as potent, selective PDE2 inhibitorsGregori J Morriello, Michael P Dwyer, Yili Chen, et al.
Molecular Cancer Therapeutics|February 16, 2011
Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screeningTimothy J Guzi, Kamil Paruch, Michael P Dwyer, et al.
Cell|June 2, 2026
Plant cell wall-plasma membrane attachments mediate stress resilience through cellulose synthase complexes and remorinsYue Rui, Magda Zaoralová, William P Dwyer, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitorsMichael P Dwyer, Kamil Paruch, Carmen Alvarez, et al.
Lancet (London, England)|March 7, 2026
Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trialMichel Azizi, Jenifer M Brown, Jamie P Dwyer, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|August 24, 2025
Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24John M Flack, Michel Azizi, Jenifer M Brown, et al.
Pageof 26